Department of Pathology, The Johns Hopkins Medical Institutions, Baltimore, MD, USA.
Am J Surg Pathol. 2011 Oct;35(10):1586-91. doi: 10.1097/PAS.0b013e31822d5cff.
Distinction of hydatidiform moles (HM) from nonmolar specimens and their subclassification as complete (CHM) versus partial hydatidiform mole (PHM) are important for clinical practice and investigational studies to refine ascertainment of risk of persistent gestational trophoblastic disease (GTD), which differs among these entities. Immunohistochemical analysis of p57 expression, a paternally imprinted maternally expressed gene on 11p15.5, and molecular genotyping are useful for improving diagnosis. CHMs are characterized by androgenetic diploidy, with loss of p57 expression due to lack of maternal DNA. Loss of p57 expression distinguishes CHMs from both PHMs (diandric triploidy) and nonmolar specimens (biparental diploidy), which retain expression. We report a unique HM characterized by morphologic features suggesting an early CHM, including lack of p57 expression by immunohistochemistry, but with genetic features more in keeping with a PHM. Specifically, molecular genotyping by short tandem repeat markers provided evidence to support interpretation as a PHM by demonstrating allele patterns and ratios most consistent with diandric triploidy, with evidence of loss of the maternal copy of chromosome 11 to explain the lack of p57 expression. This case illustrates the value of combined traditional pathologic and ancillary molecular techniques for refined diagnosis of molar specimens. It also raises questions regarding which modalities should be used to ultimately define the subtypes of HMs and whether chromosomal losses or gains, particularly involving imprinted genes such as p57, might play a role in modifying risk of persistent GTD.
葡萄胎(HM)与非葡萄胎标本的鉴别及其完全性(CHM)与部分性葡萄胎(PHM)的分类对于临床实践和研究很重要,有助于明确这些实体之间存在的持续性滋养细胞肿瘤(GTD)风险。p57 表达的免疫组织化学分析、11p15.5 上父系印迹母系表达的基因,以及分子基因分型有助于提高诊断准确性。CHM 表现为二倍体雄核型,由于缺乏母系 DNA,导致 p57 表达缺失。p57 表达缺失将 CHM 与 PHM(二倍体三体型)和非葡萄胎标本(二倍体双体型)区分开来,后两者保留表达。我们报告了一个独特的 HM,其形态特征提示为早期 CHM,包括免疫组织化学缺乏 p57 表达,但遗传特征更符合 PHM。具体而言,短串联重复标记的分子基因分型提供了支持 PHM 解释的证据,通过显示最符合二倍体三体型的等位基因模式和比例,以及 11 号染色体母本拷贝缺失来解释 p57 表达缺失,从而支持这一解释。该病例说明了传统病理和辅助分子技术联合应用对提高葡萄胎标本诊断的价值。它还提出了关于应该使用哪些模式最终定义 HM 亚型的问题,以及染色体缺失或获得,特别是涉及印迹基因如 p57,是否可能在改变持续性 GTD 风险方面发挥作用。